Press What’s news at AbelsonTaylor Group
Select category
Moving Into 2024
Applying his background in pharmacology, Jeff Berg, President of AbelsonTaylor Group, discusses a particularly exciting use of AI in drug discovery that is tackling one of biology’s biggest challenges – predicting the 3D shape of proteins and designing them from scratch. Read more at https://www.pharmalive.com/healthcare-agency-roundtable-2024-moving-into-2025/
Media Contact:
Recent Posts
Amy Restko Promoted to Vice President, Engagement Strategy at AbelsonTaylor Group
AbelsonTaylor Group today announced the promotion of Amy Restko to Vice President, Engagement Strategy. A strategic leader with expertise in...
Read Press Read more Amy Restko Promoted to Vice President, Engagement Strategy at AbelsonTaylor GroupCybersecurity considerations in pharma marketing: Trust must come first
“Responsible AI adoption is essential to protecting our clients, our agency, and the patients ultimately served by the work we...
In the News Read more Cybersecurity considerations in pharma marketing: Trust must come firstThe Leadership Circle: Kelly Ofman and the New Era of Pharma Communication
AbelsonTaylor Group’s current VP & Account Director analyzes the challenges of launching category-defining therapies, managing brands under global scrutiny, and...
In the News Read more The Leadership Circle: Kelly Ofman and the New Era of Pharma CommunicationConnect with us
Find out what's top of mind for the people reimagining health and wellness advertising.